A comparative randomized clinical trial to assess the effectiveness of the diode lasers in both contact and non-contact mode and 0.1% triamcinolone acetonide mouth paste in treatment of oral ulcers—an in vivo study

2020 ◽  
Vol 4 (1) ◽  
pp. 33-42
Author(s):  
Manmeet Kour ◽  
Anshuman Dwivedi
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Triamcinolone Acetonide ◽  
Diode Lasers ◽  
In Vivo Study ◽  
Contact Mode ◽  
Oral Ulcers

Adjunctive Triamcinolone Acetonide for Ahmed Glaucoma Valve Implantation: A Randomized Clinical Trial

2016 ◽  
Vol 27 (4) ◽  
pp. 411-416 ◽  
Author(s):  
Shahin Yazdani ◽  
Azadeh Doozandeh ◽  
Mohammad Pakravan ◽  
Vahid Ownagh ◽  
Mehdi Yaseri
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Triamcinolone Acetonide ◽  
Mixed Model ◽  
Linear Mixed Model ◽  
Final Analysis ◽  
Ahmed Glaucoma Valve ◽  
Hypertensive Phase ◽  
The Difference ◽  
Valve Implantation

Purpose To evaluate the effect of intraoperative sub-Tenon injection of triamcinolone acetonide (TA) as an adjunct to Ahmed glaucoma valve (AGV) implantation. Methods In this triple-blind randomized clinical trial, 104 eyes with refractory glaucoma were randomly assigned to conventional AGV (non-TA group) or AGV with adjunctive triamcinolone (TA group). In the TA group, 10 mg TA was injected in the sub-Tenon space around the AGV plate intraoperatively. Patients were followed for 1 year. The main outcome measure was intraocular pressure (IOP). Other outcome measures included best-corrected visual acuity (BCVA), occurrence of hypertensive phase (HP), peak IOP, number of antiglaucoma medications, and complications. Results A total of 90 patients were included in the final analysis. Mean IOP was lower in the TA group at most follow-up visits; however, the difference was statistically significant only at the first month (p = 0.004). Linear mixed model showed that mean IOP was 1.5 mm Hg lower in the TA group throughout the study period (p = 0.006). Peak postoperative IOP was significantly lower in the TA group (19.3 ± 4.8 mm Hg versus 29 ± 9.2 mm Hg, p = 0.032). Rates of success (defined as 6 < IOP <21 mm Hg) were similar in both groups at 12 months. There was no difference in the occurrence of the HP between the 2 groups (p = 0.123). Loss of BCVA >2 lines was more common in the non-TA group (p = 0.032). Conclusions Adjunctive intraoperative TA injection during AGV implantation can blunt peak IOP levels and reduce mean IOP up to 1 year. Visual outcomes also seem to be superior to standard surgery.

Sign in / Sign up

Export Citation Format

Share Document